Viva Vision Biotech key facts
as of Oct 2026- Developer and manufacturer of innovative ophthalmology therapeutics and ophthalmic formulations designed for anterior and posterior segment eye diseases.
- Viva Vision Biotech is valued at approximately $256.6M as of Oct 2026 (last reported valuation).
- It has raised $107.4M; the latest was IPO in Feb 2026.
- Notable investors include HSG (Hong Kong), Guangdong Technology Financial Group, Lapam Capital, V-Capital, Shenzhen GTJA Investment Group — 26 tracked in total.
- Status: In IPO Registration.
Viva Vision Biotech's last reported valuation, Nov 2025. Nothing priced has surfaced since.
- ·The complete investor list: 26 names
- ·Watch Viva Vision Biotech: the Monday email on marks, rounds and moves
Viva Vision Biotech funding rounds
No funding rounds for Viva Vision Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Viva Vision Biotech
26+Viva Vision Biotech valuation
Viva Vision Biotech's last reported valuation was $257 million in Nov 2025. No priced round, secondary trade or fund mark has surfaced since.
Viva Vision Biotech investors
26 investors are on record for Viva Vision Biotech, including HSG (Hong Kong), Guangdong Technology Financial Group, Lapam Capital and V-Capital.
About Viva Vision Biotech
Developer and manufacturer of innovative ophthalmology therapeutics and ophthalmic formulations designed for anterior and posterior segment eye diseases. The company provides clinical-stage drug candidates and a robust R&D pipeline, enabling patients and healthcare systems with novel treatment options, improved efficacy, and solutions for unmet ocular medical needs.
- Sector
- Healthcare
- HQ
- Wenzhou, China
- Founded
- 2016
- Employees
- 63
- Website
- vivavisionbio.com/
- Ownership
- In IPO Registration
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.